Spyre CMO sells 8,333 shares after option exercise

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale. Sloan exercised stock options to acquire 8,333 shares of common stock at $27.46 per share, then sold 8,333 shares in an open‑market transaction at $75.00 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Sloan continues to hold 8,333 common shares directly and 313,334 stock options exercisable for common stock, with the option award originally covering 400,000 shares and expiring on October 1, 2034.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,333 shares ($396K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Sloan Sheldon

Role Chief Medical Officer

Sold 8,333 shs ($625K)

Approx. gross sale proceeds $625K

Approx. exercise cost $229K

Approx. pre-tax spread $396K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	8,333	$0.00	$0.00
Exercise	Common Stock	8,333	$27.46	$229K
Sale	Common Stock	8,333	$75.00	$625K

Holdings After Transaction: Stock Option (Right to Buy) — 313,334 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Shares sold: 8,333 shares Sale price: $75.00 per share Shares exercised: 8,333 shares +3 more

6 metrics

Shares sold 8,333 shares Common stock sold in open-market transaction at $75.00

Sale price $75.00 per share Price for 8,333 common shares sold

Shares exercised 8,333 shares Common shares acquired via option exercise at $27.46

Option exercise price $27.46 per share Exercise price for stock options

Options remaining 313,334 options Stock options outstanding after transaction, expiring October 1, 2034

Original option award size 400,000 shares Total shares underlying option grant subject to vesting

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an expiration date of 2034-10-01"

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

open-market sale financial

"transaction_action: open-market sale for 8,333 common shares at $75.0000"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting in monthly installments financial

"remaining three quarters vesting in monthly installments over the following three years"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Spyre Therapeutics (SYRE) report for Sheldon Sloan?

Spyre Therapeutics reported that Chief Medical Officer Sheldon Sloan exercised stock options for 8,333 common shares and sold 8,333 shares in an open-market transaction. These moves combine a derivative exercise with a matching share sale on the same date.

How many Spyre Therapeutics (SYRE) shares did the CMO sell and at what price?

Sheldon Sloan sold 8,333 shares of Spyre Therapeutics common stock at a price of $75.00 per share. This was an open-market transaction, reported with code “S” for a sale in the Form 4 filing for the specified date.

What options did the Spyre Therapeutics (SYRE) CMO exercise in this Form 4?

Sloan exercised stock options covering 8,333 shares of Spyre Therapeutics common stock at an exercise price of $27.46 per share. These options are part of a larger award originally representing the right to purchase 400,000 shares, subject to vesting conditions.

Does the Spyre Therapeutics (SYRE) CMO still hold options after this transaction?

Yes. After the reported transactions, Sloan holds 313,334 stock options with an exercise price of $27.46 per share. These options relate to an award expiring on October 1, 2034, and continue vesting according to the stated schedule.

Was the Spyre Therapeutics (SYRE) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that the reported sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Such plans pre-arrange trades, helping separate routine liquidity from discretionary timing decisions.

What is the vesting schedule of the Spyre Therapeutics (SYRE) CMO’s option award?

The option award initially covered 400,000 shares of common stock. One quarter vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over three years, contingent on continued employment with Spyre Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 09:32 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sloan Sheldon

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		M⁽¹⁾		8,333	A	$27.46	8,333	D
Common Stock	06/03/2026		S⁽¹⁾		8,333	D	$75	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$27.46	06/03/2026		M⁽¹⁾			8,333	⁽²⁾	10/01/2034	Common Stock	8,333	$0	313,334	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR